Pulmonx Corp (LUNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmonx Corp (LUNG) has a cash flow conversion efficiency ratio of -0.133x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.21 Million) by net assets ($39.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Pulmonx Corp market cap and net worth for the company's overall valuation and market capitalisation.
Pulmonx Corp - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Pulmonx Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pulmonx Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmonx Corp ranked by their cash flow conversion efficiency. See debt repayment capacity of Pulmonx Corp to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C-Media Electronics
TWO:6237
|
0.016x |
|
Chemcon Speciality Chemicals Limited
NSE:CHEMCON
|
0.070x |
|
Zeder Investments Ltd
JSE:ZED
|
0.180x |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
-0.002x |
|
Jinro Distillers Co. Ltd
KQ:018120
|
0.107x |
|
Precot Limited
NSE:PRECOT
|
0.013x |
|
Passus S.A.
WAR:PAS
|
0.419x |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
0.045x |
Annual Cash Flow Conversion Efficiency for Pulmonx Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pulmonx Corp from 2013 to 2025. View LUNG stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $54.12 Million | $-32.45 Million | -0.600x | -63.14% |
| 2024-12-31 | $85.81 Million | $-31.54 Million | -0.368x | -15.62% |
| 2023-12-31 | $118.31 Million | $-37.61 Million | -0.318x | -8.46% |
| 2022-12-31 | $154.01 Million | $-45.14 Million | -0.293x | -36.70% |
| 2021-12-31 | $193.24 Million | $-41.43 Million | -0.214x | -58.27% |
| 2020-12-31 | $226.13 Million | $-30.63 Million | -0.135x | -222.24% |
| 2019-12-31 | $-187.38 Million | $-20.77 Million | 0.111x | +0.81% |
| 2018-12-31 | $-167.33 Million | $-18.39 Million | 0.110x | -99.85% |
| 2017-12-31 | $-63.18K | $-4.64 Million | 73.407x | +10136.98% |
| 2016-12-31 | $-2.84 Million | $-2.03 Million | 0.717x | -25.61% |
| 2015-12-31 | $-2.65 Million | $-2.56 Million | 0.964x | +1.67% |
| 2014-12-31 | $-1.41 Million | $-1.34 Million | 0.948x | +107.46% |
| 2013-12-31 | $-1.78 Million | $-811.78K | 0.457x | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more